RA Capital Healthcare Fund LP 4
4 · Artiva Biotherapeutics, Inc. · Filed Jul 14, 2026
Research Summary
AI-generated summary of this filing
Artiva (ARTV) 10% Owner RA Capital Buys Shares
What Happened
- RA Capital Management, L.P. (a reported 10% owner) made open-market purchases of Artiva Biotherapeutics (ARTV) stock. The filing reports a 7/10/2026 purchase of 15,102 shares at a weighted average price of $8.97 (≈ $135,465) and a 7/13/2026 purchase of 6,552 shares at a weighted average price of $8.94 (≈ $58,575). Total acquired: 21,654 shares for roughly $194,040. Purchases are generally viewed as a bullish signal (versus sales), though institutional purchases can reflect portfolio management decisions.
Key Details
- Transaction dates and prices:
- 2026-07-10: 15,102 shares at $8.97 (weighted average); reported price range for these trades: $8.89–$9.00 (footnote F1).
- 2026-07-13: 6,552 shares at $8.94 (weighted average); reported price range for these trades: $8.89–$8.95 (footnote F4).
- Shares owned after the transaction: not specified in the provided filing excerpt.
- Filing date: 2026-07-14. Because one purchase occurred on 2026-07-10, the consolidated Form 4 filing appears late for that earlier trade (typically Form 4s are due within two business days); the 7/13 trade was filed promptly on 7/14.
- Notable footnotes:
- The trades were executed across multiple transactions (hence weighted average prices and reported ranges; RA Capital can provide per-trade detail on request — F1, F4).
- Purchases were made by RA Capital-managed vehicles (the Adviser manages the Fund, Nexus Fund, Nexus III, and an Account). Specific holdings are reported as held directly by those vehicles (see footnotes F2–F7). The adviser and certain principals disclaim direct beneficial ownership except for pecuniary interests (F2).
- Other remark: Laura Stoppel, a Principal of the Adviser, serves on Artiva’s board of directors (as noted in the filing).
Context
- This is institutional buying by an investment manager and its funds/accounts—not an individual executive making a personal trade. Institutional purchases can reflect conviction by the manager or routine portfolio adjustments; the filing itself is factual and does not state intent. If you follow insider activity, purchases by a 10% holder are notable but should be considered alongside other signals (company news, fundamentals, and larger trading activity).
Insider Transaction Report
Form 4
RA CAPITAL MANAGEMENT, L.P.
Director10% Owner
Transactions
- Purchase
Common Stock
[F1][F2][F3]2026-07-10$8.97/sh+15,102$135,465→ 16,811,021 total(indirect: See footnotes) - Purchase
Common Stock
[F4][F2][F3]2026-07-13$8.94/sh+6,552$58,575→ 16,817,573 total(indirect: See footnotes)
Holdings
- 264,571(indirect: See footnotes)
Common Stock
[F2][F5] - 826,832(indirect: See footnotes)
Common Stock
[F2][F6] - 68,320(indirect: See footnotes)
Common Stock
[F2][F7]
Footnotes (7)
- [F1]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $9.00 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F2]RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund"), RA Capital Nexus III Fund, L.P. (the "Nexus Fund III"), and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Fund, the Nexus Fund, the Nexus Fund III, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
- [F3]Held directly by the Fund.
- [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.89 to $8.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
- [F5]Held directly by the Nexus Fund.
- [F6]Held directly by Nexus Fund III.
- [F7]Held directly by the Account.